PT  - JOURNAL ARTICLE
AU  - Falck-Jones, Sara
AU  - Vangeti, Sindhu
AU  - Yu, Meng
AU  - Falck-Jones, Ryan
AU  - Cagigi, Alberto
AU  - Badolati, Isabella
AU  - Österberg, Björn
AU  - Lautenbach, Maximilian Julius
AU  - Åhlberg, Eric
AU  - Lin, Ang
AU  - Szurgot, Inga
AU  - Lenart, Klara
AU  - Hellgren, Fredrika
AU  - Sälde, Jörgen
AU  - Albert, Jan
AU  - Johansson, Niclas
AU  - Bell, Max
AU  - Loré, Karin
AU  - Färnert, Anna
AU  - Smed-Sörensen, Anna
TI  - Functional myeloid-derived suppressor cells expand in blood but not airways of COVID-19 patients and predict disease severity
AID  - 10.1101/2020.09.08.20190272
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.08.20190272
4099  - http://medrxiv.org/content/early/2020/09/09/2020.09.08.20190272.short
4100  - http://medrxiv.org/content/early/2020/09/09/2020.09.08.20190272.full
AB  - The immunopathology of COVID-19 remains enigmatic, exhibiting immunodysregulation and T cell lymphopenia. Monocytic myeloid-derived suppressor cells (M-MDSC) are T cell suppressors that expand in inflammatory conditions, but their role in acute respiratory infections remains unclear. We studied blood and airways of COVID-19 patients across disease severity at multiple timepoints. M-MDSC frequencies were elevated in blood but not in nasopharyngeal or endotracheal aspirates of COVID-19 patients compared to controls. M-MDSCs isolated from COVID-19 patients suppressed T cell proliferation and IFNγ production partly via an arginase-1 (Arg-1) dependent mechanism. Furthermore, patients showed increased Arg-1 and IL-6 plasma levels. COVID-19 patients had fewer T cells, and displayed downregulated expression of the CD3ζ chain. Ordinal regression showed that early M-MDSC frequency predicted subsequent disease severity. In conclusion, M-MDSCs expand in blood of COVID-19 patients, suppress T cells and strongly associate with disease severity, suggesting a role for M-MDSCs in the dysregulated COVID-19 immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from the Swedish Research Council, the Swedish Heart-Lung Foundation, the Bill and Melinda Gates Foundation, the Knut and Alice Wallenberg Foundation and Karolinska Institutet.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regional Ethical Review Board Stockholm, Dnr: 2015/1949-31/4All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, ASS, upon reasonable request.